Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The bone mineral surface refers to the exposed surface of the hydroxyapatite and other calcium phosphate mineral crystals found within bone tissue. This surface provides the interface for the attachment and activity of bone cells—including osteoclasts, which resorb bone by adhering to and dissolving the bone mineral surface, and osteoblasts, which lay down new mineralized bone. The mineral phase is primarily hydroxyapatite, often with carbonate and other substitutions, and the surface is hydrated and chemically dynamic. The bone mineral surface is critical for bone remodeling processes, drug interactions (notably bisphosphonates, which bind strongly to this surface), and pathological processes in metabolic bone diseases.
Targeting osteoclast/bone mineral interface to inhibit bone resorption (e.g., bisphosphonates bind to bone mineral surface and are ingested by osteoclasts, resulting in apoptosis)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bone mineral surface.